This article is more than 5 years old. Information may no longer be current.

Intravitreal triamcinolone phase 1 trial enrollment complete

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EDEN PRAIRIE, Minn. — An intravitreal implant with triamcinolone acetate for use in the treatment of patients with diabetic macular edema has completed phase 1 enrollment, the drug’s developer said in a press release.

SurModics said the trial — called STRIDE, for “Sustained triamcinolone release for inhibition of diabetic macular edema” — will assess the safety and efficacy of the company’s I-vation intravitreal implant. The I-vation intravitreal implant is “a drug delivery system that can deliver a variety of drugs on a sustained release basis for well over a year, can be implanted in a minimally invasive procedure and may be removed once the drug has been fully released,” the company said in the release.

SurModics said the implant “can be used in combination with drugs developed by other companies to provide sustained release intraocular drug delivery of their drugs.”